Katzenboyer
Freshman
- Joined
- Nov 17, 2015
- Messages
- 1,648
Not a patent .. but APPARENTLY he / his firm .. have developed software to search insurance payments AND IDENTIFY payments that have been made in error by Medicare when a primary / secondary insurer should have covered the procedure. The savings to the US government would be billions annually. Once the new security listing is approved by the securities exchange commission (if it happens!) .. the new stock name MSPR would be listed on NASDAQ .. his initial documentation stated it would be listed based on a PE ratio of 10.5:1 .. and "based on that and the projected earnings his 70% ownership of the firm would have a STOCK VALUE in excess of $20 Billion dollars". THAT IS NOT CASH .. that is restricted stock shares. Generally in a new offering 10-20% of the company is sold .. that creates the trading volume on the exchange. The remaining stock is "restricted" and can be sold in small units only with securities exchange approval .. unless his company is acquired .. then he is bought out. So .. he is wealthy in his own right via his class action law firm .. can personally fund $10 million NIL deals. Things like building a $500 million dollar stadium .. or buying the Dolphins .. are ALL predicated on the securities activities taking place.
This is partially correct.
The "proprietary software" is not his product. He will not be selling it. It's simply a way of locating claims.
Second, the MSP Recovery Act is rear-looking. Basically, Ruiz's value is in the claims he's pursuing in which insurers are on the hook for payments already made by Medicare/Medicaid. There is value in those claims (although again, I have a very hard time seeing how it's valued in the billions, since the company hasn't generated revenue despite the firm pursuing these claims for years).
But there isn't a huge value in the claims moving forward. This type of practice is no longer happening as much as it has in the past, and certainly not to the point where billions will be pouring in annually.
The other issue is that Ruiz will face stiffening competition. He's not the only firm that handles these types of claims, and the valuation seems to be based off the assumption that he has a monopoly on this work. He doesn't.